Hearing Aids Linked to Sixfold Higher Cognitive Improvement in Older Adults with MCI
The CHOICE trial found hearing aid users with mild cognitive impairment were nearly six times more likely to show cognitive improvement than controls.
Summary
The CHOICE trial tested whether hearing aids could slow cognitive decline in 703 older adults with mild cognitive impairment and hearing loss. While the primary goal — reducing conversion to dementia — did not reach statistical significance, a striking secondary finding emerged: 15% of hearing aid users showed measurable cognitive improvement versus just 2.4% of controls, a nearly sixfold difference. Researchers from Shanghai Jiao Tong University caution that low dementia conversion rates left the trial underpowered for its primary outcome, so the null result should not be read as proof of no benefit. The secondary signal, described as a 'surprisingly giant effect size,' suggests hearing aids may actively restore cognitive and functional capacity in high-risk older adults, not merely slow decline.
Detailed Summary
Hearing loss is one of the most important modifiable risk factors for dementia, yet evidence that treating it can reverse cognitive decline has remained elusive. The CHOICE trial, conducted across six sites in Shanghai from 2021 to 2026, set out to test whether fitting hearing aids could reduce the rate at which older adults with mild cognitive impairment (MCI) convert to full dementia.
The primary outcome — dementia conversion based on Clinical Dementia Rating scores — was 3.09% in the hearing aid group versus 4.74% in controls, yielding a relative risk of 0.59. That 41% relative reduction sounds meaningful, but the P-value of 0.23 means it did not reach statistical significance. The reason: far fewer participants converted to dementia than the researchers anticipated, leaving the trial underpowered for its primary endpoint.
The secondary finding, however, was dramatic. Cognitive improvement occurred in 15.34% of hearing aid users compared with just 2.36% of controls — a relative risk of 5.94 (P<0.001). Lead researcher Hao Wu, MD, PhD, described this as evidence that treating hearing loss may help a meaningful minority of older adults with MCI regain everyday cognitive and functional capacity, not merely slow decline.
Editorialists from Columbia University Irving Medical Center drew a direct connection to the earlier ACHIEVE trial, which found a 48% relative reduction in cognitive change among high-risk participants who received a hearing intervention. Together, the two trials suggest the protective effect of hearing aids is concentrated in people already at elevated risk for cognitive decline — those with MCI, not cognitively intact adults.
Caveats are important. The effect size in CHOICE is large enough to demand replication before firm conclusions can be drawn. The study was conducted exclusively in Shanghai, limiting generalizability. Still, the findings reinforce that addressing hearing loss early in the dementia-risk window may be one of the most accessible and impactful brain-health interventions available to aging adults.
Key Findings
- Hearing aid users with MCI were nearly 6x more likely to show cognitive improvement than controls (15.3% vs 2.4%).
- Dementia conversion rate trended lower in the hearing aid group (3.1% vs 4.7%) but did not reach statistical significance.
- The trial was underpowered for its primary outcome due to lower-than-expected dementia conversion rates.
- Benefits appear concentrated in high-risk individuals with existing MCI, consistent with the ACHIEVE trial subgroup analysis.
- Treating hearing loss may actively restore cognitive and functional capacity, not simply delay further decline.
Methodology
This is a news report summarizing the CHOICE randomized controlled trial published in JAMA Neurology, a high-credibility peer-reviewed journal. The trial enrolled 703 older adults across six sites and ran from 2021 to 2026. An editorial from Columbia University researchers provides independent expert commentary alongside the primary findings.
Study Limitations
The primary outcome was underpowered due to lower-than-expected dementia conversion rates, so the null finding does not rule out benefit. The study was conducted solely in Shanghai, which may limit generalizability to other populations. The large secondary effect size requires independent replication before it can guide clinical practice.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: